CF PHARMTECH (02652) announced on April 27, 2026, a key clinical advancement in the field of respiratory interventional medical device treatment. The first patient treated with its independently developed endobronchial valve (EBV) for severe emphysema showed positive postoperative outcomes and has successfully completed the clinical observation phase. This progress marks the company's achievement in building a systematic pipeline from inhaled drugs to interventional devices, further strengthening its comprehensive capabilities in providing holistic solutions for respiratory diseases.
The endobronchial valve (EBV) is an innovative medical device strategically developed by CF PHARMTECH for the minimally invasive treatment of emphysema in chronic obstructive pulmonary disease (COPD). Emphysema is a progressive and irreversible lung condition characterized by destruction of alveolar structures, lung hyperinflation, and air trapping, significantly impairing patients' quality of life. The EBV procedure uses minimally invasive bronchoscopy to implant valves in the airways of the most damaged lung lobes, allowing overinflated tissue to gradually collapse and improving the function of healthier lung areas. This offers a new treatment option for severe emphysema patients who do not respond well to drug therapy.
The successful completion of treatment and observation for the first patient represents a major milestone in the EBV project's development and provides valuable experience for advancing subsequent clinical trials.
As an integrated innovative pharmaceutical company focused on the research, development, production, and commercialization of inhaled formulations and respiratory diseases, CF PHARMTECH has established a product portfolio covering multiple conditions including asthma, COPD, and allergic rhinitis. The company possesses five core technology platforms: particle engineering, device design, product performance evaluation, clinical development, and process engineering, which support the simultaneous development of innovative drugs and devices.
The steady progress of the EBV project extends the company's reach from inhaled drug therapies to interventional device treatments, creating a comprehensive disease management solution that spans from pharmaceutical intervention for mild-to-moderate conditions to device intervention for severe cases. This further strengthens the company's integrated positioning in the respiratory disease treatment landscape.
The global and Chinese respiratory disease markets present substantial opportunities. COPD is one of the most common chronic respiratory diseases in China, with a large population of emphysema patients facing limited existing drug treatment options and significant unmet clinical needs. As an interventional treatment method already recommended by international clinical guidelines, EBV has the potential to deliver tangible clinical benefits to severe emphysema patients.
CF PHARMTECH will continue to efficiently advance clinical research for projects like EBV while deepening the synergistic development of inhaled formulations and innovative devices. The company remains committed to providing more and better treatment options for patients with respiratory diseases and contributing to the advancement of respiratory health initiatives.